News
20. 03. 2026 Eveliqure enters into a strategic collaboration and licence agreement with Serum Institute of India for the development, manufacturing and commercialisation of ShigETEC for paediatric populations | Download
23. 07. 2025 Eveliqure Announces Dosing of First Participants in a Phase 2b study of the ShigETEC
Vaccine in Shigellosis | Download
18. 12. 2023 Eveliqure initiates clinical safety and immunogenicity trials of its vaccine candidate against Shigellosis and ETEC in endemic populations in Bangladesh | Download
23. 02. 2022 Eveliqure announces the publication of positive Phase I clinical data for its vaccine candidate against Shigellosis and ETEC | Download
19. 11. 2020 Eveliqure announces the publication of key preclinical data for its clinical stage vaccine candidate against Shigellosis and ETEC | Download
24. 09. 2020 Eveliqure announces the initiation of a Phase 1 clinical study of its combined Shigella and ETEC vaccine candidate | Download
09. 09. 2020 Eveliqure announces the award of a NIAID contract to finance Phase 2 clinical studies of its combined Shigella and ETEC vaccine candidate | Download
30. 06. 2020 Eveliqure secures further private investment to support development of its combined Shigella and ETEC vaccine candidate | Download
02. 06. 2020 Eveliqure announces regulatory approval to commence first clinical studies with its combined Shigella and ETEC vaccine | Download
05. 11. 2019 Eveliqure's effort to develop a Shigella-ETEC combination vaccine for travelers and children in resource poor countries is supported by the Wellcome Trust | Download
25. 10. 2019 The Austrian Research Promotion Agency (FFG) featured Eveliqure and the SHIGETECVAX Horizon2020 consortium project in its 'Success Story' series | Read
10. 09. 2019 Eveliqure's diarrhoea vaccine to advance towards clinical trials supported by significant Horizon2020 award. | Download